Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics

Daniel Munblit; Matthew Greenhawt; Helen A. Brough; Anna Pushkareva; Diana Karimova; Anastasia Demidova; John O. Warner; Omer Kalayci; Anna Sediva; Eva Untersmayr; Pablo Rodriguez del Rio; Marta Vazquez‐Ortiz; Stefania Arasi; Montserrat Alvaro‐Lozano; Sophia Tsabouri; Elena Galli; Burcin Beken; Philippe A. Eigenmann

doi:10.1111/pai.13851

Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics

Daniel Munblit, Matthew Greenhawt, Helen A. Brough, Anna Pushkareva, Diana Karimova, Anastasia Demidova, John O. Warner, Omer Kalayci, Anna Sediva, Eva Untersmayr, Pablo Rodriguez del Rio, Marta Vazquez‐Ortiz, Stefania Arasi, Montserrat Alvaro‐Lozano, Sophia Tsabouri, Elena Galli, Burcin Beken, Philippe A. Eigenmann

Women & Children's Health

Inflammation, Repair and Development Section, Faculty of Medicine, National Heart and Lung Institute Imperial College London London UK
Section of Allergy and Clinical Immunology, Children's Hospital Colorado University of Colorado School of Medicine Aurora Colorado USA
European Academy of Allergy and Clinical Immunology (EAACI) Zurich Switzerland
Pediatric Allergy and Asthma, School of Medicine Hacettepe University Ankara Turkey
Department of Immunology, 2nd Medical Faculty Charles University and Motol University Hospital Prague Czech Republic
Institute Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Division of Comparative Immunology and Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Allergy Department, Hospital Infantil Universitario del Niño Jesús, Madrid, Spain.
Translational Research in Pediatric Specialities Area, Division of Allergy, IRCCS Bambino Gesù Children's Hospital Rome Italy
Allergology and Clinical Immunology Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu Universitat de Barcelona Barcelona Spain
Child Health Department University of Ioannina School of Medicine Ioannina Greece
Pediatric Allergology Unit, Department of Pediatric Medicine S.Pietro Hospital Fatebenefratelli Rome Italy
Department of Pediatric Allergy and Immunology Acibadem University School of Medicine Istanbul Turkey
Geneva University Hospitals

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence.

Original language	English
Journal	Pediatric Allergy and Immunology
Volume	33
Issue number	10
DOIs	https://doi.org/10.1111/pai.13851
Publication status	E-pub ahead of print - 30 Sept 2022

Keywords

Immunology
Immunology and Allergy
Pediatrics, Perinatology and Child Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/pai.13851Licence: CC BY-NC

Cite this

Munblit, D., Greenhawt, M., Brough, H. A., Pushkareva, A., Karimova, D., Demidova, A., Warner, J. O., Kalayci, O., Sediva, A., Untersmayr, E., Rodriguez del Rio, P., Vazquez‐Ortiz, M., Arasi, S., Alvaro‐Lozano, M., Tsabouri, S., Galli, E., Beken, B., & Eigenmann, P. A. (2022). Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics. Pediatric Allergy and Immunology, 33(10). Advance online publication. https://doi.org/10.1111/pai.13851

@article{23282bb1249549ac8d7a16381ee7a99c,

title = "Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics",

abstract = "By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence.",

keywords = "Immunology, Immunology and Allergy, Pediatrics, Perinatology and Child Health",

author = "Daniel Munblit and Matthew Greenhawt and Brough, {Helen A.} and Anna Pushkareva and Diana Karimova and Anastasia Demidova and Warner, {John O.} and Omer Kalayci and Anna Sediva and Eva Untersmayr and {Rodriguez del Rio}, Pablo and Marta Vazquez‐Ortiz and Stefania Arasi and Montserrat Alvaro‐Lozano and Sophia Tsabouri and Elena Galli and Burcin Beken and Eigenmann, {Philippe A.}",

year = "2022",

month = sep,

day = "30",

doi = "10.1111/pai.13851",

language = "English",

volume = "33",

journal = "Pediatric Allergy and Immunology",

issn = "0905-6157",

publisher = "Blackwell Munksgaard",

number = "10",

}

Munblit, D, Greenhawt, M, Brough, HA, Pushkareva, A, Karimova, D, Demidova, A, Warner, JO, Kalayci, O, Sediva, A, Untersmayr, E, Rodriguez del Rio, P, Vazquez‐Ortiz, M, Arasi, S, Alvaro‐Lozano, M, Tsabouri, S, Galli, E, Beken, B & Eigenmann, PA 2022, 'Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics', Pediatric Allergy and Immunology, vol. 33, no. 10. https://doi.org/10.1111/pai.13851

TY - JOUR

T1 - Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics

AU - Munblit, Daniel

AU - Greenhawt, Matthew

AU - Brough, Helen A.

AU - Pushkareva, Anna

AU - Karimova, Diana

AU - Demidova, Anastasia

AU - Warner, John O.

AU - Kalayci, Omer

AU - Sediva, Anna

AU - Untersmayr, Eva

AU - Rodriguez del Rio, Pablo

AU - Vazquez‐Ortiz, Marta

AU - Arasi, Stefania

AU - Alvaro‐Lozano, Montserrat

AU - Tsabouri, Sophia

AU - Galli, Elena

AU - Beken, Burcin

AU - Eigenmann, Philippe A.

PY - 2022/9/30

Y1 - 2022/9/30

N2 - By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence.

AB - By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence.

KW - Immunology

KW - Immunology and Allergy

KW - Pediatrics, Perinatology and Child Health

U2 - 10.1111/pai.13851

DO - 10.1111/pai.13851

M3 - Article

SN - 0905-6157

VL - 33

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

IS - 10

ER -

Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this